Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Noradrenergic function and clinical outcome in antidepressant pharmacotherapy
Autore:
Miller, HL; Ekstrom, RD; Mason, GA; Lydiard, RB; Golden, RN;
Indirizzi:
Univ N Carolina, Dept Psychiat, Sch Med, Chapel Hill, NC 27599 USA Univ N Carolina Chapel Hill NC USA 27599 h Med, Chapel Hill, NC 27599 USA Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA Med Univ S Carolina Charleston SC USA 29425 iat, Charleston, SC 29425 USA
Titolo Testata:
NEUROPSYCHOPHARMACOLOGY
fascicolo: 6, volume: 24, anno: 2001,
pagine: 617 - 623
SICI:
0893-133X(200106)24:6<617:NFACOI>2.0.ZU;2-O
Fonte:
ISI
Lingua:
ENG
Soggetto:
BETA-ADRENERGIC STIMULATION; HUMAN-PLASMA MELATONIN; DEPRESSED-PATIENTS; NOREPINEPHRINE TURNOVER; N-ACETYLTRANSFERASE; PINEAL-GLAND; DESIPRAMINE; SECRETION; 6-SULFATOXYMELATONIN; EXCRETION;
Keywords:
antidepressants; melatonin; norepinephrine; pineal gland; depression;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
38
Recensione:
Indirizzi per estratti:
Indirizzo: Golden, RN Univ N Carolina, Dept Psychiat, Sch Med, Campus Box 7160, Chapel Hill, NC 27599 USA Univ N Carolina Campus Box 7160 Chapel Hill NC USA 27599 99 USA
Citazione:
H.L. Miller et al., "Noradrenergic function and clinical outcome in antidepressant pharmacotherapy", NEUROPSYCH, 24(6), 2001, pp. 617-623

Abstract

Controversy remains regarding the role of noradrenergic systems in determining clinical response to antidepressant pharmacotherapy. Pineal gland production of melatonin can serve as a physiologic index of noradrenergic function. The aim of this study was to examine the effects of antidepressant treatment on 24-hour urinary excretion of the principle metabolite of melatonin, 6-sulfatoxymelatonin in treatment responders and nonresponders. Twenty-four outpatients meeting DSM-III-R criteria for Major Depression received treatment with either fluvoxamine or imipramine for 6 weeks while participating in a placebo-controlled double-blind clinical trial. Twenty-four hour excretion of 6-sulfatoxymetaltonin was measured at baseline and at the conclusion of the treatment trial. Changes in urinary excretion of 6-sulfatoxymelatonin distinguished antidepressant responders from nonresponders, with a significant increase observed in the former group and a significant decreasein the latter. The degree of clinical response was correlated with the change in 6-sulfatoxymelatonin excretion. These results suggest that enhanced noradrenergic function may play an important role in determining clinical response to antidepressant pharmacotherapy. (C) 2001 American College of Neuropsychopharmacology. Published by Elsevier Science Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/01/20 alle ore 21:01:35